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Retinal artery occlusion is 
associated with compositional 
and functional shifts in the 
gut microbiome and altered 
trimethylamine-n-oxide levels
Denise c. Zysset-Burri1,2*, Irene Keller2,3, Lieselotte E. Berger1, Peter J. neyer  4,5, 
christian Steuer  6, Sebastian Wolf  1,2 & Martin S. Zinkernagel1,2
Retinal artery occlusion (RAo) is a sight threatening complication of cardiovascular disease and 
commonly occurs due to underlying atherosclerosis. As cardiovascular disease and atherosclerosis 
in particular has been associated with compositional alterations in the gut microbiome, we 
investigated this association in patients with clinically confirmed non-arteritic RAO compared to 
age- and sex-matched controls. On the phylum level, the relative abundance of Bacteroidetes was 
decreased in patients with RAO compared to controls, whereas the opposite applied for the phylum 
of Proteobacteria. Several genera and species such as Actinobacter, Bifidobacterium spp., Bacteroides 
stercoris, Faecalibacterium prausnitzii were relatively enriched in patients with RAO, whereas 
others such as Odoribacter, Parasutterella or Lachnospiraceae were significantly lower. Patient’s 
gut microbiomes were enriched in genes of the cholesterol metabolism pathway. The gut derived, 
pro-atherogenic metabolite trimethylamine-N-oxide (TMAO) was significantly higher in patients 
with RAo compared to controls (p = 0.023) and a negative correlation between relative abundances 
of genera Parasutterella and Lachnospiraceae and tMAo levels and a positive correlation between 
relative abundance of genus Akkermansia and TMAO levels was found in study subjects. Our findings 
proposes that RAO is associated with alterations in the gut microbiome and with elevated TMAO levels, 
suggesting that RAo could be targeted by microbiome-altering interventions.
Acute retinal arterial occlusive disorders comprise one of the major causes of acute visual loss. Acute occlusion 
of central or branch retinal arteries termed retinal artery occlusion (RAO), may result in ischemia of the inner 
retina with initial swelling and eventually atrophy and painless monocular loss of vision (Fig. 1)1. The patho-
genesis of RAO is primarily thromboembolic, often from carotid plaques, and therefore closely associated with 
atherosclerosis2,3. Factors contributing to atherosclerosis and cardiovascular disease in general arise mainly from 
environmental sources or a combination of genetic and environmental causes. Diet has been identified as the 
major risk factor for cardiovascular disease with a positive correlation with total and low-density lipoprotein 
(LDL) cholesterol and an inverse correlation with high-density lipoprotein (HDL) cholesterol4,5. Additional risk 
factors include elevated blood pressure, cigarette smoking and diabetes mellitus.
Digestion of macronutrients, consisting of carbohydrates, proteins, fats and fibers, results in a myriad of 
metabolites that enter the circulation. The gut microbiome has been shown to be integral to digestion and con-
tributes to a substantial portion of the variation in blood lipids6. Furthermore, it can generate nutrients from 
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substrates that are otherwise not degradable by the host7. Alterations in the gut microbiome have been associated 
with cardiovascular disease and atherosclerosis8–10. Furthermore, links between the gut microbiome and diabetes 
mellitus and obesity have been revealed in the last decade, both of which are associated with atherosclerosis11–13. 
In addition, in retinal diseases such as age related macular degeneration, which is the leading cause of irrevers-
ible severe visual loss in the western world and has been associated with atherosclerosis14, alterations in the gut 
microbiota have been described15,16. However, a possible link between alterations in the gut microbiota and RAO 
has so far not been investigated.
The exact mechanisms linking the gut microbiota with the development of atherosclerosis have not yet mate-
rialized. Several studies have reported a link between choline diet–induced trimethylamine N-oxide (TMAO) 
production in the gut and cardiovascular disease9,10,17. Dysbiosis in the gut has been shown to lead to increased 
permeability of the intestine, which in turn causes increased systemic levels of bacterial products resulting in 
low-grade chronic inflammation18. This may directly affect atherogenesis and may lead to the development of 
insulin resistance with concomitant effects on plasma lipids19.
In this study, we performed a systematic analysis of the gut microbiome and associated metabolic pathways 
and analyzed TMAO levels as well as genes of the TMAO synthesis pathway in patients with symptomatic RAO 
and controls.
Results
taxonomic characterization of the gut microbiome. To investigate if the intestinal microbiome is 
associated with the occurrence of RAO, we sequenced the gut metagenomes of 29 patients with clinically con-
firmed non-arteritic RAO and 30 healthy age- and sex-matched controls (Table 1). In total, we generated 1.77 
billion 151 bp paired-end reads, i.e. on average, 31 ± 12.6 (s.d.) million reads per sample. After trimming and 
filtering, we obtained 28 ± 11.7 (s.d.) million non-human high-quality reads per sample for further process-
ing. The majority of the mapped reads were bacterial (99.9 ± 0.10% in patients and 99.7 ± 0.9% (s.d.) in con-
trols) and dominated by the phyla Bacteroidetes and Firmicutes, followed by Proteobacteria and Actinobacteria 
(Fig. 2a,b). The most abundant classes in our cohort were Bacteroidia and Clostridia consistent with previous 
observations20,21. The microbiome composition was dominated by the genera Bacteroides and Alistipes, followed 
by Subdoligranulum, Prevotella and Faecalibacterium (Fig. 2c,d). The most abundant species was Subdoligranulum 
Figure 1. Representative images of a patient with central retinal artery occlusion. Top: Representative color 
photographs of the unaffected right eye and the left eye with typical features of a central artery occlusion with 
ischemia and edema of the retina and a cherry red spot. Bottom: Optical coherence tomography (OCT) images 
of the same patient showing a scan through the right retina. Swelling of the inner retinal layers is evident due to 
occlusion of the central retinal artery.
3Scientific RepoRtS |         (2019) 9:15303  | https://doi.org/10.1038/s41598-019-51698-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
Feature
Patients 
(n = 29)
Controls 
(n = 30)
P value RAO vs 
CTRL
Males (n) 15 14 0.80∆
Age (years) 69.4 ± 1.9 69.0 ± 1.7 0.93*
Current smoker (n) 5 3 0.47∆
Previous smoker (n) 12 10 0.60∆
BMI (kg/m2) 27.6 ± 0.8 25.8 ± 0.7 0.10*
Table 1. Characteristics of study patients. BMI, body mass index; CTRL, control; RAO, retinal artery occlusion. 
Data are mean ± s.d., ∆Fisher’s exact test, *Welch’s t test.
Figure 2. Taxonomic characterization of the gut microbiome. Relative abundances of microbiota at phyla 
level in all study subjects (a) and averaged for study groups (b). There is a decrease in relative abundance of 
Bacteroidetes with respect to Proteobacteria in the RAO cohort. Relative abundances of microbiota at genus level 
in all study subjects (c) and averaged for study goups (d). There is a decrease of Bacteroides in the RAO group 
compared to controls. CTRL, c ontrol (n = 30); RAO, retinal artery occlusion (n = 29).
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species, followed by Faecalibacterium prausnitzii, Prevotella copri, Alistipes putredinis and Akkermansia 
muciniphila.
enterotypes and distinct microbial composition in the cohort. A previous study has suggested 
that the human intestinal microbiome can be divided into three enterotypes of distinct microbial composition20. 
According to this study, we calculated the Jensen-Shannon distance of the genus abundances and clustered the 
samples with partitioning around medoids (PAM). Graphical interpretation in Fig. 3a was done using between 
class analysis (BCA) of the genus compositions as suggested in Arumugam et al.20, which visualizes results from 
principal component analysis (PCA) and clustering. The enterotypes were characterized by the following contrib-
utors at genus level: Bacteroides was the driving genus of enterotype 1, Eubacterium of enterotype 2 and Prevotella 
contributed to enterotype 3 (Fig. 3b). Applying Fisher’s exact test, no association between the enterotypes and the 
disease status could be detected, showing an uniform distribution of the samples across the three enterotypes.
A PCA with the health status as grouping variable showed that differences in microbial species abun-
dance separated the patient group from the control group, with permutation multivariate analysis of variance 
(PERMANOVA) confirming a significant p value of 0.001 (Fig. 4a). To identify taxa that are different in relative 
abundance between RAO and controls, the linear discriminant analysis effect size algorithm LEfSe was applied 
Figure 3. Gut enterotypes in the cohort. Three enterotypes exist in the cohort based on the abundance of 
microbial genera. Patients (n = 29) and controls (n = 30) are denoted by squares (□) and triangles (∆), 
respectively (a). Boxplots represent the abundance of Bacteroides, Eubacterium and Prevotella, the proposed 
drivers of the three enterotypes (b). Blue is enterotype 1, purple is enterotype 2 and orange is enterotype 3.
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on the previously identified microbiome. The class Actinobacteria and the species Bifidobacterium adolescentis, 
Bifidobacterium bifidum, Bacteroides stercoris and Faecalibacterium prasnitzii were enriched in RAO, whereas 
the family Lachnospiraceae and the genera Odoribacter and Parasutterella were enriched in controls (p < 0.05, 
Kruskal-Wallis test; Fig. 4b,c).
Figure 4. Distinct microbial composition between retinal artery occlusion (RAO) patients and control. (a) 
Principal component analysis of microbial species abundance grouped patients and controls separately, with 
PERMANOVA confirming a significant difference between the groups (p = 0.001). (b) Box plots representing the 
mean abundance +/− s.d. of bacterial genera and species associated with RAO (Kruskal-Wallis test, p < 0.05). (c) 
LDA (linear discriminant analysis) score plot of differentially abundant taxonomic features among groups (LDA 
score for discriminative features >2.0). Red is patients (RAO, n = 29), green is controls (CTRL, n = 30).
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Metabolic features of altered gut microbiome. To describe the metabolic functions of the microbiome, 
the Metagenomic Phylogenetic Analysis tool HUMAnN2 was applied on each sample separately based on the 
identified taxonomic profiles. Resulting organism-specific gene hits were functionally assigned to pathways using 
MinPath and their relative abundances were evaluated. A PCA with the health status as grouping variable showed 
that differences in abundance of metabolic functions separated the patient group from the control group, with 
PERMANOVA confirming a significant p value of 0.003 (Fig. 5a). In total 5 abundant metabolic pathways and 10 
gene families (i.e. occurring in at least 30 samples) were identified differing between RAO patients and controls 
(p < 0.05, Kruskal-Wallis test), illustrating that there were functional aspects of the gut microbiome associated 
with RAO. Enriched metabolic functions in the microbiome of patients and controls were assessed by integrating 
the gene families with metabolic pathways. We used UniProt for protein identification, and based on the KEGG 
PATHWAY Database we identified pathways involved in secondary metabolite biosynthesis. The pantothenate 
and coenzyme A biosynthesis (map 00770) was the highest abundant metabolic pathway and was enriched in 
the gut microbiome of RAO patients. Coenzyme A is an essential cofactor for cell growth and is involved in 
many metabolic reactions including the synthesis and degradation of fatty acids23. Consequently, we also found 
several metabolites enriched in the microbiome of patients that were involved in metabolic reactions such as iso-
prene biosynthesis, pathway of geranylgernaly-diphosphate and methylerythritol phosphate, whereas metabolites 
involved in the L-histidine biosynthesis pathway were enriched in the microbiome of controls (Fig. 5b).
concentrations of trimethylamine-n-oxide (tMAo). To assess the TMAO concentration and cor-
relation to metagenomic data, a subgroup analysis with 12 RAO patients and 11 age- and sex-matched controls 
was performed. The TMAO concentration was significantly higher in patients with RAO compared to controls 
(5.26 ± 2.26 µmol/L versus 3.31 ± 1.44 µmol/L (s.d.), p = 0.023; Fig. 6A). Multivariate analysis using MaAsLin 
found a negative correlation between relative abundances of genera Parasutterella and Lachnospiraceae and 
TMAO levels and a positive correlation between relative abundance of genus Akkermansia and TMAO levels in 
study subjects. However, no significant differences in the TMAO level among the three enterotypes of Fig. 3 could 
be found (p > 0.05, Kruskal-Wallis test, Fig. 6B). In order to examine the TMAO-forming potential of microbes in 
the cohort as well as in the TMAO subgroup, metagenomic reads were BLASTed against a database for key genes 
Figure 5. Species-specific microbial pathways associated with retinal artery occlusion (RAO). (a) Principal 
component analysis of microbial pathway abundance grouped patients and controls separately, with 
PERMANOVA confirming a significant difference between the groups (p = 0.003). (b) Box plots representing 
the abundance of pathways associated with RAO and illustration of the respective pathways which differed in 
patients with RAO and control subjects (Kruskal-Wallis test, p < 0.05). Red is patients (RAO, n = 29), green is 
controls (CTRL, n = 30).
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of the TMAO synthesis pathway, encoding choline trimethylamine-lyase (cutC) and carnitine oxygenase (cntA)24. 
The abundances of key genes of both pathways were elevated in the patient group (mean values of 0.00097% and 
0.0011% for cutC and cntA, respectively) compared to controls (mean values of 0.00043% and 0.00017% for cutC 
and cntA, respectively) as percentage of total reads. However, these observed differences were statistically not 
significant (p > 0.05, Fisher’s exact test, Fig. 6c,d).
Discussion
In this study, we identified several compositional and functional alterations of the gut microbiome that may be 
related to RAO which is closely associated with atherosclerosis. Atherosclerotic disease is characterized by lipid 
accumulation and recruitment of macrophages to the arterial wall forming plaques. It has been shown that ath-
erosclerotic plaques contain bacterial DNA with phylotypes common to the gut microbiota and that the amount 
of bacterial DNA in the plaque correlate with inflammation25. Furthermore, Karlsson et al. suggested that the gut 
microbiome is associated with the inflammatory status of the host and patients with symptomatic atherosclerosis 
exhibit characteristic changes in the gut microbiota, including a higher abundance of the genus Collinsella in 
patients and of Roseburia and Eubacterium in healthy controls8.
The healthy human gut microbiome is known to be stable over time26,27. Generally, the phyla Bacteroidetes and 
Firmicutes dominate the gut microbial community followed by Proteobacteria and Actinobacteria28 as observed 
in our cohort. However, diseases associated with metabolism and immune responses result in an imbalanced 
unstable state of the microbiome, called dysbiosis. Dysbiosis is well documented in metabolic disorders including 
an increase in relative abundance of Firmicutes with respect to Bacteroidetes29,30. Furthermore, an elevated preva-
lence of Proteobacteria has been proposed as a diagnostic marker for dysbiosis and risk of disease28. In our study, 
there is a decrease of Bacteroidetes (39.2% in patients vs 46.7% in controls) with respect to Proteobacteria (10.8% 
in patients vs 5.4% in controls) in RAO patients (Fig. 2b), suggesting a correlation between atherosclerotic disease 
and dysbiosis.
Figure 6. Trimethylamine-N-oxide (TMAO) concentration associated with retinal artery occlusion (RAO). 
(a) The TMAO concentration was significantly higher in a subgroup of 12 RAO patients compared to 11 
controls (Fisher’s exact test, p = 0.023). (b) No significant difference in the TMAO concentration among the 
three enterotypes has been found (Kruskal Wallis test, p > 0.05). Abundance of carnitine oxygenase (cntA, c) 
and choline trimethylamine-lyase (cutC, d) in patients (RAO, n = 29) and controls (CTRL, n = 30) as well as in 
the TMAO subgroup of 12 patients (RAO TMAO) and 11 controls (CTRL TMAO) as percentage of total reads. 
Obtained p values (Fisher’s exact test) are indicated. Red is patient (RAO), green is controls (CTRL), blue is 
enterotype 1, purple is enterotype 2 and orange is enterotype 3.
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At the taxonomical level, we observed associations between RAO and microbiome composition, and further-
more, PCA and PERMANOVA on microbial species abundance confirmed a separation of patients and controls 
by microbiome composition (Fig. 4a). Previous studies have identified a higher abundance of Collinsella, a genus 
of Actinobacteria in the gut of patients with symptomatic atherosclerosis, which is in keeping with our data. 
Several studies have identified bacterial DNA in human atherosclerotic plaque samples of which a high propor-
tion could be attributed to Actinobacteria25,31. DNA contained in atherosclerotic plaques have been shown to 
resemble the phylotypes common to the gut microbiota and therefore support the hypothesis that the gut micro-
biota can be sources for atherosclerotic plaque-associated bacteria25.
The higher abundance of two Bifidobacterium species in our RAO cohort is surprising. Bifidobacterium species 
have received considerable attention mainly as common probiotics and have been implicated to have a ben-
eficial effect on blood lipid concentrations. A meta-analysis of 30 randomized controlled trials revealed that 
probiotic bacteria supplementation resulted in significantly lower concentrations of total cholesterol and LDL 
cholesterol. However, probiotic supplementation did not change levels of HDL cholesterol or triglycerides, both 
of which are associated with the development of atherosclerosis32. On the other hand, higher proportions of 
Bifidobacterium species have been implicated in inflammatory bowel disease which in turn is associated with early 
atherosclerosis33–35.
However, sequencing the microbial genes is not enough because the presence of DNA alone does not neces-
sarily translate into protein synthesis and function affecting the host. Functional annotation analysis indicated 
that metabolic pathways are enriched or decreased in patients with RAO. Furthermore, PCA and PERMANOVA 
on abundance of metabolic functions confirmed a separation of patients and controls by functional features of 
the gut microbiome (Fig. 5a). The isoprene biosynthesis pathway, also known as the mevalonate pathway, was 
enriched in patients with RAO. This pathway converts mevalonate into sterol isoprenoids, such as cholesterol, 
and is best known as the target of statins, a class of cholesterol lowering drugs. Likewise, the methylerythritol 
phosphate pathway was enriched in RAO patients. This pathway is a source of isoprene units in most bacteria that 
are key intermediates in the pathway from acetate to cholesterol36.
In our study, we found a significant difference in TMAO levels between patients with RAO and controls. 
TMAO is believed to be pro-atherogenic and has been associated with cardiovascular risks by promoting foam 
cell formation and interfering with cholesterol transport37,38. In humans, TMAO is produced from choline 
and carnitine by the gut microbiota. The main producers of TMAO derive from the two phyla Firmicutes and 
Proteobacteria and include Escherichia fergusonii, Proteus penneri, Providencia rettgeri, Anaerococcus hydrogena-
lis, Clostridium asparagiforme, and Edwardsiella tarda39,40. In our study, we found a negative association between 
the TMAO concentration and Parasutterella and Lachnospiraceae, which is consistent with the upregulation of 
these genera in controls (Fig. 4). Moreover, the positive correlation found between the TMAO concentration and 
Akkermansia is consistent with previous observations39. However, whether increased levels of TMAO are quin-
tessentially causative for atherosclerosis or whether they merely represent a biomarker of differences in the gut 
microbiome remains to be investigated.
Our findings indicate that patients with RAO may have alterations in gene expression pathways related to 
cholesterol production. This is especially interesting in view of recent findings that enteric microbiome metab-
olites have been shown to correlate with response to simvastatin treatment41. Statins are HMG-CoA reductase 
inhibitors and are commonly used to reduce plasma levels of LDL cholesterol in order to prevent coronary artery 
disease42. Further studies are needed to confirm functional differences in the gut microbiome by correlating met-
abolic profiles and quantification of messenger RNA in patients with atherosclerosis. However, as the prognostic 
information is limited because of possible confounders due to genetic background and nutritional and environ-
mental habits of patients and controls, further studies are necessary. On its own, our findings are hypothesis gen-
erating for further trials investigating the impact of the gut microbiome on atherosclerosis mediated ophthalmic 
diseases.
conclusions
This study shows compositional and functional alterations in the gut microbiome and evelated TMAO levels in 
patients with RAO, and therefore may have implications on preventative strategies for this vision threatening 
disease.
Methods
Study design and recruitment. Participants (n = 59) were recruited from the Department of 
Ophthalmology of the University Hospital Bern (Inselspital), Switzerland. The study was conducted in accordance 
with the Declaration of Helsinki and approved by the Ethics Committee of the Canton of Bern (ClinicalTrials.gov: 
NCT02438111). After receiving oral and written information, all participants gave written informed consent to 
participate in the study. All participants were subjected to an ophthalmic examination including optical coher-
ence tomography and standard fundus color photography. Patients (n = 29) had clinically confirmed non-arteritic 
RAO and the control group (n = 30) was selected to represent an age- and sex-matched group with no sign of 
RAO. We tested for differences between the two groups in a range of demographic values using either Welch’s t 
test (for age and BMI) or Fisher’s exact test (for gender and smoking; Table 1). Exclusion criteria for both groups 
were chronic inflammatory and gastrointestinal diseases (including previous surgery in the gastrointestinal tract) 
and use of systemic antibiotics within the last three months.
Sequencing and data control. Stool samples were brought chilled to the study center within 16 hours 
after fecal output where they were immediately frozen at −20 °C. Metagenomic DNA was isolated from up to 
200 mg of stool sample using the PSP® Spin Stool DNA Plus kit (Stratec Biomedical AG, Beringen, Switzerland) 
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according to the manufacturer’s protocol with an integrated RNA digestion step using 100 mg/ml RNase A 
(Qiagen, Hombrechtikon, Switzerland). The DNA was brought to the Next Generation Sequencing Platform of 
the University of Bern, Switzerland, for metagenomic shotgun sequencing. The TruSeq DNA PCR-Free Library 
Preparation kit was used for library preparation for sequencing following standard pipelines of the Illumina 
HiSeq 3000 platform with up to ten samples pooled in one lane. The resulting 150 bp paired-end reads were 
quality filtered with Trimmomatic v.0.3243. To remove sequences of human origin, all reads were mapped to 
the human reference genome hg19 using Bowtie2 v.2.2.444 and only the unmapped reads were used for further 
analysis.
Microbial and functional profiling. For taxonomical analysis, the high-quality non-human reads were 
mapped against a set of clade-specific marker sequences using the Metagenomic Phylogenetic Analysis tool 
v.2.6.0 (MetaPhlAn2) and the marker database v.2045 using default settings. In order to provide the relative abun-
dance of each taxonomic unit, Bowtie2 v.2.2.4 was applied for alignment followed by normalization of the total 
number of reads in each clade by the nucleotide length of its marker.
To describe the metabolic potential of the identified microbes, the HMP (Human Microbiome Project46) 
Unified Metabolic Analysis Network (HUMAnN2 v.0.11.022) was applied using default settings. HUMAnN2 
assesses the abundance (reads per kilobase; RPK) of gene families and pathways in each sample, to provide a 
functional interpretation of the metagenomic sequences. HUMAnN2 was run for each sample separately, includ-
ing information of the taxonomic profiles from MetaPhlAn2. For nucleotide-level searches, Bowtie2 v.2.2.4 was 
applied to map reads to the functionally annotated pangenome database ChocoPhlAn. All unmapped reads 
were used for translated searches against the universal protein reference database UniRef9047 applying Diamond 
v.0.8.3748. The resulting organism-specific gene hits were assigned to pathways using MinPath v.1.249, finally pro-
viding a set of pathways including their abundances. The R package ade450 was used to perform PCA providing 
global analysis of microbial species abundance and pathway abundance between RAO and controls. A visualiza-
tion of the individual samples grouped by case and control is provided in Figs 4a and 5a. Permutation multivar-
iate analysis of variance (PERMANOVA) using the R package vegan51 was assessed with 1000 permutations to 
calculate a p value for separation.
To identify taxonomic and functional features with significantly different relative abundances in RAO and 
controls, the linear discriminant analysis effect size (LEfSe) algorithm52 was applied using default settings. A 
difference was considered to be statistically significant if p < 0.05 (KruskalKruskal-Wallis test) and LDA score ≥2.
Measurement of trimethylamine-n-oxide (tMAo). TMAO was obtained from Alfa Aesar (Kandel, 
Germany), ammonium formate and formic acid from Sigma (Buchs, Switzerland) and all reagents were of the 
highest analytical grad available. Solvents (water, methanol, acetonitrile) were also obtained from Sigma and 
of mass spectrometry grade. Blood plasma (EDTA) samples were obtained from a fasting subgroup including 
12 RAO patients and 11 controls and stored at −80 °C until analysis which was performed as published previ-
ously53. In short: Samples were thawed at room temperature, 25 µL aliquots were transferred to reaction cups and 
diluted with 225 µL of methanol containing the deuterated internal standard (TMAO-d9, Cambridge Isotope 
Laboratories, Andover, USA). After ten minutes and complete protein precipitation, the cups were briefly agitated 
and spun in a micro centrifuge at 15 000 g for 10 minutes. Chromatographic analysis was done using an UltiMate 
3000 chromatographic system (Thermo Fisher Scientific, Reinach, Switzerland) coupled to a triple quadrupole 
mass spectrometer (Sciex QTRAP 5500, Darmstadt, Germany). Supernatant was injected onto a hydrophilic 
interaction column (Phenomenex, Luna 3 µm HILIC 200 Å, 150 × 4.6 mm). Separation was done using a linear 
gradient starting at 1.5 minutes post-injection from 100% of mobile phase A (10 mM ammonium formate in 
acetonitrile) to 90% of mobile phase B (10 mM ammonium formate in water, adjusted to pH 4 with formic acid) 
within seven minutes at a flow rate of 750 µL/min. This ratio was kept constant for another two min and the sys-
tem was re-equilibrated until a total run time of 12.5 min. Analytes were detected by monitoring specific mass 
transitions (MRM mode). Concentrations were reported in µmol/L and compared between patients and controls 
using Fisher’s exact test. To assess the association between microbial abundance and TMAO concentration, mul-
tivariate association with linear models (MaAsLin) for multivariate analysis54 applying an additive general model 
was used. Significant association was considered below a q value threshold of 0.20 after adjusting for false discov-
ery rate (FDR). To identify genes of the TMAO synthesis pathway in our metagenomics data, reads were mapped 
against the cntA/cutC database provided by Rath et al.24 using the BWA-MEM algorithm of the Burrows-Wheeler 
Alignment tool v.0.7.17. The number of mapped reads was counted by the Samtool flagstat v.1.8.
Data availability
The datasets supporting the conclusions of this article are available in the European Nucleotide Archive under 
accession number PRJEB24557.
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